These 13 new drugs are on: Hengrui, Haizheng, and Huang...

Medicine Network February 18, 2021, the haze of the epidemic has not completely subsided, multi-country new crown vaccine research and development rapidly, bringing hope to the global economy.
China's economy has taken the lead in recovering, and the pharmaceutical industry has been punching hard.
, the National Health Insurance Administration issued a "two-set approach", although the online sale of prescription drugs to be clarified, but the retail industry still saw a good.
the Spring Festival, the fourth batch of drugs set to open the bid, the normalization of collection continued to affect the development of the pharmaceutical industry, further forcing enterprises to innovate and transform.
, the new version of the medicare drug catalog will be officially launched, and drug companies will have a tougher time.
2021, move forward and see the dawn! This issue launched a domestic category 1 new drug 2021 look forward to, in order to win readers.
years, under the influence of two major policies, the pharmaceutical industry has made normal procurement and dynamic adjustment of medical insurance catalogue, generic drugs have accelerated into the era of micro-profits, and research and development innovation has become the core driving force of pharmaceutical companies.
long way of research and development innovation, when innovation has become a major trend in the pharmaceutical industry, the early layout of innovative drugs enterprises, through the continuous "strange upgrade", finally came to the key period of new drugs approved for market.
2020, 14 domestically produced new class 1 drugs (excluding preventive biological products) were approved by the State Drug Administration for the first time.
five of these drugs are tinib drugs, including sorfantinib, BTK inhibitors Zebutini and eboutinib, third-generation EGFR-TKI amedinib, and ALK inhibitor Ensatini.
among them, Zebtini of Baiji Shenzhou is the first domestic BTK inhibitor, Haussen Pharmaceuticals ametini is the first domestic third-generation EGFR-TKI targeted drug, Anda Pharmaceuticals' Ensatini is the first domestic APK inhibitor.
In addition, The phosphate emethamivir capsules of Dongsian Pharmaceuticals, the cyclophenol injections from Hesco and the benzodiaminum bromide nasal sprays from Silver Valley Pharmaceuticals are the first new Class 1 drugs approved by the company to achieve a breakthrough of zero.
2021, a new journey, a new look.
According to incomplete statistics, Hengrui Pharmaceutical's Haiqupopa, Microcore Bio's Siglita, Drug Ming Juno's Ricky Lunsay, Rongchang Bio's Tatasip, Aramco Pharmaceuticals' Contamin ... 13 domestic category 1 new drugs are expected to be approved for market this year.
is also worth noting that the first domestic oral anti-AIDS drugs, the first MET inhibitors, the first third generation BCR-ABL inhibitors ... It is expected to be born in 2021.
13 domestic class 1 new drugs expected to be approved for sale by 2021 Source: MED2.0 China Drug Review Database Challenge Novaral! Hengrui TPO-R astrists can be phased Henrui Pharmaceuticals' hypoptopa ethanolamine tablets are orally absorbed small molecules of non-peptide-promoting plateatoplasm-promoting plateatoplasm -adhesives (TPO-R) astrists used to treat patients with severe regenerative disorder anemia (SAA) who are ineffective in immunosuppressive therapy (IST).
currently has five TPO-R astigators approved for the global market, including Amgen's Rotestin, Japan's Yannoyi's Reed Popa, GSK/Novarma's Aqupopa, AkaRx/Fosun Pharma's AvalancoPopa, and Sansheng Pharmaceuticals' recombinant human platelet-producing injection (Tybio).
, Luqu Popa and Rome are not listed in China.
is a common blood disorder that can be secondary to a variety of diseases, increasing the risk of bleeding while delaying the treatment process and ultimately affecting the long-term survival of patients.
Haiqupopa is a series of structural modifications carried out by Hengrui Pharmaceuticals to Aiqupopa, and the research and development of highly selective TPO-R astrists with independent intellectual property rights.
2020 global sales of $1,738 million, up 23% year-on-year, according to the company's 2000-meter intranet data.
Sansheng Pharmaceuticals semi-annual report shows that Tybe Australia 2020H1 sales of 1.375 billion yuan, an increase of 15.2% year-on-year, due to the inelastic medical needs of patients, its sales are less affected by the new crown outbreak.
Novarian Aiquopa global sales (units: millions of U.S. dollars) Photo Source: Minernet multinational listed company sales database Haizheng first class 1 new drug, Jian refers to the 26 billion blood lipid drug market class 1 new drug Haize mebu tablets are Haizheng Pharmaceuticals independently developed blood lipid drug, used to treat primary hypercholesterolemia.
Heizemeb has the same mechanism of action as the listed folding mebu, acting on the Nymanpik C1 class 1 (NPC1L1) protein receptor on the surface of the intestine and liver cells, selectively inhibiting the absorption of cholesterol, thereby reducing the transfer of cholesterol from the small intestine to the liver, reducing the storage of liver cholesterol and increasing the removal of cholesterol in the blood. according to
meters of intranet data, in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal sales of blood lipid-lowering drugs exceeded 26 billion yuan, of which 510 million yuan was sales of wheat cloth.
2020, Zetia's global sales will be $482 million, according to Merca East.
China's public medical institutions terminal blood lipid drug sales source: Minet China's public medical institutions terminal competition pattern Haize mebu tablets are the first Haizheng Pharmaceuticals to declare the listing of a new class of drugs, its research and development investment has reached 280 million yuan, some brokerages predict that its approval is expected to become a billion-class heavy varieties.
addition, Haizheng Pharmaceuticals in the study of a new class of drugs and anti-tumor drug HS234 tablets, HS236 capsules, etc. , have entered Phase I clinical trials.
the first domestic oral anti-AIDS drug! Real Biology, Eddie Pharmaceuticals competition in July 2020, Real Biology, Eddie Pharmaceuticals has submitted oral anti-AIDS class 1 new drug Azfding tablets, ACC007 tablets of the market application, and in August 2020 was included in the priority review.
ACC007 is a new structure of non-nucleoside reverse transcriptase inhibitors, for Eddie Pharmaceuticals' first anti-AIDS class 1 new drugs, was included in the National 13th Five-Year Plan "major new drug creation" science and technology major special projects.
AzfD is the world's first anti-HIV dual-target innovative drug, the first class 1 new drug reported for real life, access to the national "major new drug creation" science and technology major project support, has been in China, the United States, Europe and other global patents and licensed.
AIDS is a serious threat to human health of the world disease.
WHO statistics, there are currently more than 38 million AIDS patients worldwide.
the global market for anti-HIV drugs will be $33.96 billion in 2018 and is expected to reach $46.75 billion in 2023, according to public data released by the U.S. Government.
At present, there is no complete cure of AIDS drugs, clinical use of 3 or more drugs combined use (cocktail therapy) to treat AIDS, and China's drugs to imported drugs and domestic generic drugs as the lead.
domestic enterprises cutting-edge biology injection with AbbotVetay is the world's first long-acting anti-AIDS new drug, and the first domestic oral anti-AIDS new drug has not yet been born, Eddie Pharmaceuticals, real life who can be the first to be approved, it is worth looking forward to.
The 5th domestic PD-1, Zhengda Tianqing and Kangfang Sprint Pai Ampli (AK105) single anti-injection is a class 1 innovative drug jointly developed and commercialized by Kangfang Bio and Zhengtian Qing Pharmaceutical Industry, the main adaptive disorders include liver cancer, stomach cancer, lung cancer, Hodgkin's lymphoma, nasopharyngeal cancer and other diseases.
Pai Ampley's first application for the market is classic Hodgkin's lymphoma, and phase III clinical trials are under way for adaptations such as non-scale non-small cell lung cancer and squamous non-small cell lung cancer.
Pai Aapley Clinical Trials Source: Minet China Drug Clinical Trials Publicizes Koupai Ampley's Fc subjectivity and complement-mediated ability to be completely removed through Fc zone mutations, while the antigen binding dissocation rate is slower than that of foreign listed PD-1 antibodies.
these features make Pianpre more effective in blocking the activity of the PD-1 path, and maintaining stronger T-cell anti-tumor activity, promising to be a better clinically-available anti-PD-1 drug.
the current domestic listed PD-1 includes two imported PD-1 and four domestic PD-1.
In December 2020, Henrui Pharmaceuticals' Karelli Pearl Single Resistance, Xinda Bio's Xindili Mono-Resistance, Baiji Shenzhou's Tyreli Pearl Single Resistance, Reusi Bio's Terripley Single Resistance 4 domestic PD-1s were added to the new version of the health care negotiation catalogue.
2020, Global sales of Keytruda will be $14.38 billion, up 30 percent from a year earlier, according to Merca East.
,992 million U.S. dollars, down 3 percent from a year earlier.
20 billion market! The first MET inhibitors, three generations of ABL inhibitors to attack the current domestic anti-tumor drug research and development of tinib as the representative of the pile, showing a "big explosion" situation.
, or tyrosine kinase inhibitor, is a small molecular protein kinase inhibitor that blocks one or more protein kinases.
2019, sales of terminal protein kinase inhibitors in china's public medical institutions exceeded 20 billion yuan, up 59.53 percent year-on-year, according to the company's internal network data.
can be seen that the market potential of tinitic drugs is huge.
China's public medical institutions terminal protein kinase inhibitor sales source: Minet China's public medical institutions terminal competition pattern of the first domestic third-generation EGFR-TKI inhibitors have been spent on Howson Pharmaceuticals, Alice's efotinib tablets, Eisen Pharmaceuticals' Malay acid Avetini capsules are also expected to be approved for the market.
addition, MET inhibitors and ABL inhibitors in tinibic drugs are also worth looking forward to. Class
1 new drug volitinib is an oral small molecule MET inhibitor developed by Huang Pharmaceuticals, whose new drug market application for the treatment of non-small cell lung cancer has been included in the priority review, is the first selected MET inhibitor to submit a listing application, is expected to become the first domestic listing of MET inhibitors.
Oribatini is a new class 1 drug developed by Asahan Pharmaceuticals subsidiary Guangzhou Shunjian, which is an oral third-generation BCR-ABL inhibitor, which has outstanding effects on BCR-ABL and a variety of BCR-ABL mutants, including T315I mutations, and is expected to become the first third-generation BCR-ABL inhibitor to be listed in China.
source: Mi Net database, data statistics if there are omissions, welcome to point out!